APA (7th ed.) Citation

K, D., J, B., D, L., J, C., RB, S., & D, A. (2023). Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis. HIV medicine, 24(3), 279. https://doi.org/10.1111/hiv.13377

Chicago Style (17th ed.) Citation

K, Dunn, Bushen J, Luo D, Cai J, Simonson RB, and Anderson D. "Darunavir/cobicistat/emtricitabine/tenofovir Alafenamide in Treatment-naïve (AMBER) and Virologically Suppressed (EMERALD) Participants with Neurological And/or Psychiatric Comorbidities: Week 96 Subgroup Analysis." HIV Medicine 24, no. 3 (2023): 279. https://doi.org/10.1111/hiv.13377.

MLA (9th ed.) Citation

K, Dunn, et al. "Darunavir/cobicistat/emtricitabine/tenofovir Alafenamide in Treatment-naïve (AMBER) and Virologically Suppressed (EMERALD) Participants with Neurological And/or Psychiatric Comorbidities: Week 96 Subgroup Analysis." HIV Medicine, vol. 24, no. 3, 2023, p. 279, https://doi.org/10.1111/hiv.13377.